Oh In-Jae相关文献与解析，生知库 | 链接生命科学的每一步

Clinical implications of plasma EGFR T790M and ctDNA shedding across metastatic sites in plasma- or tissue-confirmed EGFR-mutant non-small cell lung cancer treated with lazertinib: a prospective multicenter cohort study

血浆或组织证实存在EGFR突变的非小细胞肺癌患者接受拉泽替尼治疗后，血浆EGFR T790M和ctDNA在转移部位脱落的临床意义：一项前瞻性多中心队列研究

doi:10.21037/tlcr-2025-aw-1216

Kim, Min Jee; Jung, Junghee; Ji, Wonjun; Choi, Chang-Min; Kim, Seung Joon; Cho, Hyung Jun; Hwang, Yong Gi; Kim, Eun Young; Lee, Shin Yup; Yoo, Seung Soo; Choi, Sunha; Oh, In-Jae; Kim, Young-Chul; Park, Chul-Kyu; Yoon, Seong Hoon; Kim, Yun Seong; Kim, Mi-Hyun; Lee, Min Ki; Eom, Jung Seop; Kim, Soo Han; Lee, Jeong Eun; Chung, Chaeuk; Yeo, Chang Dong; Lee, Sang Haak; Lee, Jae Cheol

Ex vivo STAT3 phosphorylation in circulating immune cells: a novel biomarker for early cancer diagnosis and response to anti-PD-1 therapy

循环免疫细胞中STAT3的体外磷酸化：一种用于早期癌症诊断和抗PD-1疗法反应的新型生物标志物

期刊:Cancer Communications

影响因子:24.9

doi:10.1002/cac2.12631

Lee, Sung-Woo; Kim, Young Ju; Jeong, Saei; Rho, Kyung Na; Noh, Jeong Eun; Kim, Hee-Ok; Cho, Hyun-Ju; Choi, Yoo Duk; Yang, Deok Hwan; Hwang, Eu Chang; Bae, Woo Kyun; Yun, Sook Jung; Yun, Ju Sik; Park, Cheol-Kyu; Oh, In-Jae; Cho, Jae-Ho

Progressive accumulation of circulating CD27(-)CD28(-) effector/memory CD8(+) T cells in patients with lung cancer blunts responses to immune checkpoint inhibitor therapy

肺癌患者体内循环CD27(-)CD28(-)效应/记忆CD8(+) T细胞的逐渐积累会减弱对免疫检查点抑制剂疗法的反应。

期刊:Experimental and Molecular Medicine

影响因子:12.9

doi:10.1038/s12276-025-01448-7

Lee, Sung-Woo; Yun, Ju Sik; Kim, Young Ju; Jeong, Saei; Noh, Jeong Eun; Kim, Hee-Ok; Cho, Hyun-Ju; Park, Cheol-Kyu; Oh, In-Jae; Cho, Jae-Ho

Temporal changes in tongue color during immune checkpoint inhibitor therapy in patients with non-small-cell lung cancer: a prospective observational study using digital tongue diagnosis

非小细胞肺癌患者接受免疫检查点抑制剂治疗期间舌色变化的前瞻性观察研究：一项采用数字舌诊的前瞻性观察研究

期刊:Oncology Reviews

影响因子:5.2

doi:10.3389/or.2025.1697252

Cho, Eunbyul; Choi, Woosu; Lim, Jun Hyeok; Son, Ji Woong; Jang, Seung Hun; Lee, Seung Hyeun; Choi, Jong Gwon; Oh, In-Jae; Jang, Tae-Won; Yoon, Seong Hoon; Kim, Seung Joon; Choi, Chang-Min; Lee, Sung Yong; Ko, Mi Mi; Jeong, Mi-Kyung

Combination therapy with expanded natural killer cells and atezolizumab exerts potent antitumor immunity in small cell lung cancer

扩增自然杀伤细胞与阿特珠单抗联合疗法在小细胞肺癌中发挥强大的抗肿瘤免疫作用

期刊:Cancer Immunology Immunotherapy

影响因子:5.1

doi:10.1007/s00262-025-03997-2

Vo, Manh-Cuong; Nguyen, Van-Tan; Tran, Van-Dinh-Huan; Oh, Hyung-Joo; Jung, Sung-Hoon; Bae, Woo Kyun; Lee, Je-Jung; Oh, In-Jae

Efficacy and safety of first-generation epidermal growth factor receptor tyrosine kinase inhibitors in retreatment of patients without T790M

第一代表皮生长因子受体酪氨酸激酶抑制剂在无T790M突变患者的再治疗中的疗效和安全性

期刊:Translational Lung Cancer Research

影响因子:3.5

doi:10.21037/tlcr-2025-36

Choi, Juwhan; Lee, Jae Cheol; Kim, In Ae; Lee, Kye Young; Lee, Jeong Eun; Jang, Seung Hun; Yoon, Seong Hoon; Oh, In-Jae; Lee, Sang Hoon; Kim, Eun Young; Lee, Sung Yong

信号转导

发表日期：2025

文献求助收藏

Better Chemotherapeutic Response of Small Cell Lung Cancer in Never Smokers than in Smokers

与吸烟者相比，从不吸烟的小细胞肺癌患者对化疗的反应更好

期刊:Tuberculosis and Respiratory Diseases

影响因子:3

doi:10.4046/trd.2024.0056

Park, Ha-Young; Oh, Hyung-Joo; Park, Hwa Kyung; Yoon, Joon-Young; Yoon, Chang-Seok; Kho, Bo Gun; Kim, Tae-Ok; Shin, Hong-Joon; Park, Chul-Kyu; Kwon, Yong-Soo; Kim, Yu-Il; Lim, Sung-Chul; Kim, Young-Chul; Oh, In-Jae

Late-Onset Crizotinib-Associated Renal Cysts With Subsequent Regression Following Dose Reduction: A Case Report

克唑替尼相关肾囊肿迟发性发生，减量后消退：病例报告

期刊:Thoracic Cancer

影响因子:2.3

doi:10.1111/1759-7714.70111

Yoon, Joon-Young; Jeong, Won Gi; Choi, Yoo-Duk; Kang, Seung Ji; Park, Hwa Kyung; Oh, Hyung-Joo; Park, Cheol-Kyu; Oh, In-Jae; Kim, Young-Chul

发表日期：2025

文献求助收藏

Real-World Outcomes of Brigatinib Compared to Alectinib as a Second-Line Therapy After Crizotinib in Advanced Anaplastic Lymphoma Kinase Positive Non-Small Cell Lung Cancer Patients

在克唑替尼治疗后，布加替尼与阿来替尼作为二线疗法治疗晚期间变性淋巴瘤激酶阳性非小细胞肺癌患者的真实世界疗效比较

期刊:Thoracic Cancer

影响因子:2.3

doi:10.1111/1759-7714.70175

Kim, Min Jee; Kwak, Hyun Seok; Koh, Eun Nim; Park, Cheol-Kyu; Kim, Young-Chul; Oh, In-Jae; Kim, Seung Joon; Lim, Jun Hyeok; Ryu, Jeong-Seon; Choi, Chang Min

Immunophenotypic analysis on circulating T cells for early diagnosis of lung cancer

循环T细胞免疫表型分析在肺癌早期诊断中的应用

Clinical implications of plasma EGFR T790M and ctDNA shedding across metastatic sites in plasma- or tissue-confirmed EGFR-mutant non-small cell lung cancer treated with lazertinib: a prospective multicenter cohort study

血浆或组织证实存在EGFR突变的非小细胞肺癌患者接受拉泽替尼治疗后，血浆EGFR T790M和ctDNA在转移部位脱落的临床意义：一项前瞻性多中心队列研究

Ex vivo STAT3 phosphorylation in circulating immune cells: a novel biomarker for early cancer diagnosis and response to anti-PD-1 therapy

循环免疫细胞中STAT3的体外磷酸化：一种用于早期癌症诊断和抗PD-1疗法反应的新型生物标志物

Progressive accumulation of circulating CD27(-)CD28(-) effector/memory CD8(+) T cells in patients with lung cancer blunts responses to immune checkpoint inhibitor therapy

肺癌患者体内循环CD27(-)CD28(-)效应/记忆CD8(+) T细胞的逐渐积累会减弱对免疫检查点抑制剂疗法的反应。

Temporal changes in tongue color during immune checkpoint inhibitor therapy in patients with non-small-cell lung cancer: a prospective observational study using digital tongue diagnosis

非小细胞肺癌患者接受免疫检查点抑制剂治疗期间舌色变化的前瞻性观察研究：一项采用数字舌诊的前瞻性观察研究

Combination therapy with expanded natural killer cells and atezolizumab exerts potent antitumor immunity in small cell lung cancer

扩增自然杀伤细胞与阿特珠单抗联合疗法在小细胞肺癌中发挥强大的抗肿瘤免疫作用

Efficacy and safety of first-generation epidermal growth factor receptor tyrosine kinase inhibitors in retreatment of patients without T790M

第一代表皮生长因子受体酪氨酸激酶抑制剂在无T790M突变患者的再治疗中的疗效和安全性

Better Chemotherapeutic Response of Small Cell Lung Cancer in Never Smokers than in Smokers

与吸烟者相比，从不吸烟的小细胞肺癌患者对化疗的反应更好

Late-Onset Crizotinib-Associated Renal Cysts With Subsequent Regression Following Dose Reduction: A Case Report

克唑替尼相关肾囊肿迟发性发生，减量后消退：病例报告

Real-World Outcomes of Brigatinib Compared to Alectinib as a Second-Line Therapy After Crizotinib in Advanced Anaplastic Lymphoma Kinase Positive Non-Small Cell Lung Cancer Patients

在克唑替尼治疗后，布加替尼与阿来替尼作为二线疗法治疗晚期间变性淋巴瘤激酶阳性非小细胞肺癌患者的真实世界疗效比较